LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on VYNE stock, giving a Buy rating yesterday.
Rami Katkhuda’s rating is based on several promising developments within VYNE Therapeutics’ pipeline and financial health. The company has reported a strong cash position, which is expected to sustain operations into the second half of 2026. This financial stability is crucial for the continued development of their therapeutic candidates.
VYNE’s pipeline includes Repibresib (VYN201), which is progressing through a Phase IIb study for nonsegmental vitiligo. The drug has shown rapid clinical benefits and a favorable safety profile in earlier trials, which positions it as a potential competitor to existing treatments. Additionally, VYN202 is being evaluated for plaque psoriasis, with promising early results and further data expected by the end of 2025. These factors, combined with the potential advantages of their treatments over current standards, underpin the Buy rating.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 19.3% and a 37.50% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, VYNE Therapeutics, and Disc Medicine.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $5.75 price target.
Questions or Comments about the article? Write to editor@tipranks.com